When Should You Stop Taking Tirzepatide?

You've been told your progress isn't enough, here's what the guidance actually says

Picture this: six months in, you've moved through a couple of dose increases, and someone tells you the treatment might not be working. Before you hand the pen back, it's worth knowing what the clinical threshold is.

NICE's appraisal of tirzepatide (TA1026) says that if a patient has not achieved at least 5% reduction in body weight after six months at the highest dose they could tolerate, continuing treatment warrants a review. That is not the same as an automatic stop, it is a signal for a conversation. Some people take longer to respond. Factors like starting dose, adherence, diet and individual metabolism all feed into the picture a prescriber will look at.

One misconception worth putting to rest: many people assume that if the scale hasn't moved dramatically by month two or three, the medicine isn't working. Tirzepatide's titration schedule exists partly so your body adjusts at a pace that reduces side effects; the therapeutic effect often builds across the full titration. A slow start is not a stopped clock. That said, if your prescriber reviews the evidence at six months and it isn't adding up, our guidance on when to stop Mounjaro walks through the clinical criteria that inform whether stopping is the right call. Details on the mechanism and dose schedule for tirzepatide explain why the early weeks look different from the maintenance phase.

Side effects that make you want to stop, and what to actually do

The most common reason people consider stopping early is gastrointestinal discomfort: nausea, loose stools, reflux, that background queasiness that makes meals less appealing than they should be. This is well-documented and, for most people, time-limited. The first week or two at a new dose is usually the roughest patch; the body adjusts. Stopping permanently because of early nausea is often an overcorrection.

That said, there are side effects that should prompt you to stop taking the injection and seek medical help promptly. Severe stomach pain that radiates to your back (with or without vomiting) needs urgent assessment because it can signal pancreatitis. The MHRA highlighted acute pancreatitis in its January 2026 Drug Safety Update for GLP-1 medicines, noting it is infrequent but potentially serious. Allergic reactions, gallbladder symptoms and severe dehydration from persistent vomiting are other reasons to stop and get help, not to wait for your next review appointment.

If you are unsure whether your symptoms warrant stopping, that is exactly what the aftercare team is there for. At nume, prescribers and support are available seven days a week. You can also reach the team directly if something doesn't feel right between doses.

Life events that change the picture: surgery, pregnancy planning and contraception

Some stopping decisions have nothing to do with how well the medicine is working. They are about timing.

If you are planning surgery, your anaesthetist needs to know you are taking a GLP-1 medicine. Slowed gastric emptying raises the risk of aspiration under general anaesthesia, so NHS England advises telling your whole healthcare team (including the anaesthetist) well in advance. In practice, this usually means stopping tirzepatide before the procedure, with the exact lead time confirmed by your surgical team.

Pregnancy is a clear stopping point. Tirzepatide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. The MHRA advises using effective contraception during treatment. If you are considering coming off treatment to try for a pregnancy, your prescriber needs to be part of that conversation; they can also advise on the relevant wash-out period.

There is also a specific contraception interaction worth knowing: for the first four weeks of tirzepatide treatment, and for four weeks after each dose increase, women using oral contraceptives should add a non-oral method such as condoms. Slowed gut transit can reduce pill absorption. NHS guidance sets this out clearly, and it is one of the things our prescribers routinely flag at the start of treatment, including advice on when to take tirzepatide so that timing works around your other medications. More on what to consider when you are on tirzepatide covers this in full.

Stopping versus pausing: what actually happens next

People sometimes ask whether stopping means the weight will come back. The honest answer is: it often does, at least partially, if the lifestyle changes that should accompany treatment haven't taken hold. This is not a criticism, it reflects the biology of appetite regulation. Tirzepatide reduces hunger signals; when those signals return, eating patterns can shift back. The NHS patient information for tirzepatide notes that treatment is intended alongside a reduced-calorie diet and increased physical activity, and those habits are what support weight maintenance long-term.

A pause is different from a stop. If you are taking a break due to illness, a supply gap or a planned procedure, your prescriber should advise on whether to resume at the same dose or step back. This is covered in more detail in the guidance on how to stop tirzepatide safely.

If you are thinking about coming off treatment entirely, or are unsure whether your current results justify continuing, a clinical review is the right first step, not a decision made between you and Google at midnight. A free consultation with a nume prescriber is there for exactly that kind of question.